Understanding CLL Treatment Toxicities and Prognostic Factors

This chapter delves into the toxicities linked to chronic lymphocytic leukemia (CLL) treatments, advocating for venetoclax-based therapy in select cases. It also explores cardiovascular risks of BTK inhibitors, discusses Rechter's transformation, and outlines crucial prognostic markers for effective CLL management.